S&P 500   4,471.37 (+0.75%)
DOW   35,294.76 (+1.09%)
QQQ   368.94 (+0.63%)
AAPL   144.84 (+0.75%)
MSFT   304.21 (+0.48%)
FB   324.76 (-1.15%)
GOOGL   2,827.36 (+0.15%)
TSLA   843.03 (+3.02%)
AMZN   3,409.02 (+3.31%)
NVDA   218.62 (+0.53%)
BABA   168.00 (+0.73%)
NIO   37.71 (+3.94%)
CGC   13.35 (-2.55%)
GE   104.41 (+1.63%)
MU   67.68 (-0.18%)
AMD   112.12 (+0.12%)
T   25.70 (+0.31%)
F   15.70 (+1.62%)
ACB   7.03 (-3.17%)
DIS   176.46 (+1.18%)
PFE   41.49 (-0.43%)
BA   217.04 (-0.18%)
AMC   40.74 (+1.67%)
S&P 500   4,471.37 (+0.75%)
DOW   35,294.76 (+1.09%)
QQQ   368.94 (+0.63%)
AAPL   144.84 (+0.75%)
MSFT   304.21 (+0.48%)
FB   324.76 (-1.15%)
GOOGL   2,827.36 (+0.15%)
TSLA   843.03 (+3.02%)
AMZN   3,409.02 (+3.31%)
NVDA   218.62 (+0.53%)
BABA   168.00 (+0.73%)
NIO   37.71 (+3.94%)
CGC   13.35 (-2.55%)
GE   104.41 (+1.63%)
MU   67.68 (-0.18%)
AMD   112.12 (+0.12%)
T   25.70 (+0.31%)
F   15.70 (+1.62%)
ACB   7.03 (-3.17%)
DIS   176.46 (+1.18%)
PFE   41.49 (-0.43%)
BA   217.04 (-0.18%)
AMC   40.74 (+1.67%)
S&P 500   4,471.37 (+0.75%)
DOW   35,294.76 (+1.09%)
QQQ   368.94 (+0.63%)
AAPL   144.84 (+0.75%)
MSFT   304.21 (+0.48%)
FB   324.76 (-1.15%)
GOOGL   2,827.36 (+0.15%)
TSLA   843.03 (+3.02%)
AMZN   3,409.02 (+3.31%)
NVDA   218.62 (+0.53%)
BABA   168.00 (+0.73%)
NIO   37.71 (+3.94%)
CGC   13.35 (-2.55%)
GE   104.41 (+1.63%)
MU   67.68 (-0.18%)
AMD   112.12 (+0.12%)
T   25.70 (+0.31%)
F   15.70 (+1.62%)
ACB   7.03 (-3.17%)
DIS   176.46 (+1.18%)
PFE   41.49 (-0.43%)
BA   217.04 (-0.18%)
AMC   40.74 (+1.67%)
S&P 500   4,471.37 (+0.75%)
DOW   35,294.76 (+1.09%)
QQQ   368.94 (+0.63%)
AAPL   144.84 (+0.75%)
MSFT   304.21 (+0.48%)
FB   324.76 (-1.15%)
GOOGL   2,827.36 (+0.15%)
TSLA   843.03 (+3.02%)
AMZN   3,409.02 (+3.31%)
NVDA   218.62 (+0.53%)
BABA   168.00 (+0.73%)
NIO   37.71 (+3.94%)
CGC   13.35 (-2.55%)
GE   104.41 (+1.63%)
MU   67.68 (-0.18%)
AMD   112.12 (+0.12%)
T   25.70 (+0.31%)
F   15.70 (+1.62%)
ACB   7.03 (-3.17%)
DIS   176.46 (+1.18%)
PFE   41.49 (-0.43%)
BA   217.04 (-0.18%)
AMC   40.74 (+1.67%)
NASDAQ:MGLN

Magellan Health Stock Forecast, Price & News

$94.63
-0.11 (-0.12 %)
(As of 10/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$94.55
$94.82
50-Day Range
$94.55
$94.78
52-Week Range
$70.95
$95.43
Volume212,958 shs
Average Volume267,556 shs
Market Capitalization$2.49 billion
P/E Ratio7.95
Dividend YieldN/A
Beta1.19
30 days | 90 days | 365 days | Advanced Chart
Receive MGLN News and Ratings via Email

Sign-up to receive the latest news and ratings for Magellan Health and its competitors with MarketBeat's FREE daily newsletter.


Magellan Health logo

About Magellan Health

Magellan Health, Inc. engages in the business of healthcare management. It operates through the following segments: Healthcare, Pharmacy Management and Corporate. The Healthcare segment includes the Behavioral & Specialty Health reporting unit, which provides carve-out management services for behavioral health, employee assistance plans, and other areas of specialty healthcare. The Pharmacy Management segment comprises of services that provide clinical and financial management of pharmaceuticals paid under both the medical and the pharmacy benefit. The Corporate segment covers amounts not allocated to the Healthcare and Pharmacy Management segments. The company was founded in 1969 and is headquartered in Phoenix, AZ.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Hospitals
Sub-Industry
Managed Health Care
Sector
Medical
Current Symbol
NASDAQ:MGLN
CUSIP
55907920
Employees
9,500
Year Founded
N/A

Sales & Book Value

Annual Sales
$4.58 billion
Cash Flow
$5.57 per share
Book Value
$73.03 per share

Profitability

Net Income
$382.33 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$2.49 billion
Next Earnings Date
11/4/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

2.18 out of 5 stars

Medical Sector

380th out of 1,361 stocks

Hospitals Industry

6th out of 8 stocks

Analyst Opinion: 1.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 3.1 5 -4 -3 -2 -1 -












Magellan Health (NASDAQ:MGLN) Frequently Asked Questions

Is Magellan Health a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Magellan Health in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Magellan Health stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MGLN, but not buy additional shares or sell existing shares.
View analyst ratings for Magellan Health
or view top-rated stocks.

What stocks does MarketBeat like better than Magellan Health?

Wall Street analysts have given Magellan Health a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Magellan Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Magellan Health?

Magellan Health saw a increase in short interest during the month of September. As of September 30th, there was short interest totaling 2,470,000 shares, an increase of 36.5% from the September 15th total of 1,810,000 shares. Based on an average daily trading volume, of 220,300 shares, the days-to-cover ratio is currently 11.2 days. Approximately 9.6% of the shares of the company are sold short.
View Magellan Health's Short Interest
.

When is Magellan Health's next earnings date?

Magellan Health is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Magellan Health
.

How were Magellan Health's earnings last quarter?

Magellan Health, Inc. (NASDAQ:MGLN) announced its earnings results on Thursday, August, 5th. The company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.95 by $0.84. The business had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.14 billion. Magellan Health had a trailing twelve-month return on equity of 1.69% and a net margin of 6.50%. Magellan Health's revenue for the quarter was up 11.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.86 EPS.
View Magellan Health's earnings history
.

How has Magellan Health's stock been impacted by Coronavirus (COVID-19)?

Magellan Health's stock was trading at $53.88 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MGLN shares have increased by 75.6% and is now trading at $94.63.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MGLN?

2 analysts have issued 1 year target prices for Magellan Health's stock. Their forecasts range from $95.00 to $95.00. On average, they anticipate Magellan Health's stock price to reach $95.00 in the next year. This suggests a possible upside of 0.4% from the stock's current price.
View analysts' price targets for Magellan Health
or view top-rated stocks among Wall Street analysts.

Who are Magellan Health's key executives?

Magellan Health's management team includes the following people:
  • Kenneth J. Fasola, Chief Executive Officer & Director
  • James E. Murray, President & Chief Operating Officer
  • David Patrick Bourdon, Chief Financial Officer
  • Caroline Carney, Chief Medical Officer
  • Jeffrey N. West, Principal Accounting Officer, SVP & Controller

What is Kenneth J. Fasola's approval rating as Magellan Health's CEO?

31 employees have rated Magellan Health CEO Kenneth J. Fasola on Glassdoor.com. Kenneth J. Fasola has an approval rating of 83% among Magellan Health's employees.

Who are some of Magellan Health's key competitors?

What other stocks do shareholders of Magellan Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Magellan Health investors own include Energy Transfer (ET), General Motors (GM), NVIDIA (NVDA), The Boeing (BA), Netflix (NFLX), UnitedHealth Group (UNH), Broadcom (AVGO), Mastercard (MA), Ford Motor (F) and Overstock.com (OSTK).

What is Magellan Health's stock symbol?

Magellan Health trades on the NASDAQ under the ticker symbol "MGLN."

Who are Magellan Health's major shareholders?

Magellan Health's stock is owned by many different retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.06%), Louisiana State Employees Retirement System (0.04%) and Sphinx Trading LP (0.01%). Company insiders that own Magellan Health stock include James E Murray, Jeffrey N West and Mostafa Kamal.
View institutional ownership trends for Magellan Health
.

Which institutional investors are buying Magellan Health stock?

MGLN stock was acquired by a variety of institutional investors in the last quarter, including Sphinx Trading LP, State of Alaska Department of Revenue, and Louisiana State Employees Retirement System.
View insider buying and selling activity for Magellan Health
or or view top insider-buying stocks.

How do I buy shares of Magellan Health?

Shares of MGLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Magellan Health's stock price today?

One share of MGLN stock can currently be purchased for approximately $94.63.

How much money does Magellan Health make?

Magellan Health has a market capitalization of $2.49 billion and generates $4.58 billion in revenue each year. The company earns $382.33 million in net income (profit) each year or $0.77 on an earnings per share basis.

How many employees does Magellan Health have?

Magellan Health employs 9,500 workers across the globe.

What is Magellan Health's official website?

The official website for Magellan Health is www.magellanhealth.com.

Where are Magellan Health's headquarters?

Magellan Health is headquartered at 4801 E. Washington Street, Phoenix AZ, 85034.

How can I contact Magellan Health?

Magellan Health's mailing address is 4801 E. Washington Street, Phoenix AZ, 85034. The company can be reached via phone at (800) 642-1716 or via email at [email protected].


This page was last updated on 10/15/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.